GSA Capital Partners LLP purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 20,010 shares of the biotechnology company’s stock, valued at approximately $394,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. boosted its position in shares of Exelixis by 1.6% during the 4th quarter. BlackRock Inc. now owns 30,584,751 shares of the biotechnology company’s stock worth $601,600,000 after acquiring an additional 490,747 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Exelixis by 3.2% during the 3rd quarter. Vanguard Group Inc. now owns 26,527,089 shares of the biotechnology company’s stock worth $470,060,000 after acquiring an additional 834,478 shares in the last quarter. Vanguard Group Inc boosted its position in Exelixis by 3.2% in the third quarter. Vanguard Group Inc now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after buying an additional 834,478 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Exelixis by 8.8% in the third quarter. JPMorgan Chase & Co. now owns 5,931,216 shares of the biotechnology company’s stock valued at $105,101,000 after buying an additional 480,986 shares in the last quarter. Finally, First Trust Advisors LP boosted its position in Exelixis by 19.5% in the fourth quarter. First Trust Advisors LP now owns 5,551,138 shares of the biotechnology company’s stock valued at $109,191,000 after buying an additional 907,412 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

In related news, Director George A. Scangos sold 39,904 shares of Exelixis stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $19.64, for a total transaction of $783,714.56. Following the completion of the transaction, the director now owns 1,452,331 shares of the company’s stock, valued at $28,523,780.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Patrick J. Haley sold 8,000 shares of Exelixis stock in a transaction on Thursday, January 3rd. The stock was sold at an average price of $19.95, for a total transaction of $159,600.00. The disclosure for this sale can be found here. Insiders have sold 859,872 shares of company stock valued at $19,069,347 in the last three months. 4.80% of the stock is owned by insiders.

A number of brokerages have weighed in on EXEL. ValuEngine upgraded shares of Exelixis from a “sell” rating to a “hold” rating in a research report on Wednesday, January 9th. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Wednesday, January 9th. Cowen restated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research report on Tuesday, February 26th. Zacks Investment Research upgraded shares of Exelixis from a “strong sell” rating to a “hold” rating in a research report on Monday, March 4th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $48.00 target price on shares of Exelixis in a research report on Friday, March 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $29.20.

EXEL stock opened at $24.53 on Friday. The firm has a market cap of $7.45 billion, a PE ratio of 17.15, a price-to-earnings-growth ratio of 0.77 and a beta of 2.22. Exelixis, Inc. has a 52-week low of $13.42 and a 52-week high of $25.19. The company has a quick ratio of 8.41, a current ratio of 8.50 and a debt-to-equity ratio of 0.01.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 12th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.14. The firm had revenue of $228.60 million during the quarter, compared to the consensus estimate of $188.44 million. Exelixis had a net margin of 80.95% and a return on equity of 48.90%. The company’s revenue for the quarter was up 90.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.12 earnings per share. On average, research analysts predict that Exelixis, Inc. will post 1.04 EPS for the current year.

WARNING: “GSA Capital Partners LLP Takes Position in Exelixis, Inc. (EXEL)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/gsa-capital-partners-llp-takes-position-in-exelixis-inc-exel/2896494.html.

Exelixis Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Story: Trading Strategy Methods and Types

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.